Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy
Status:
Unknown status
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids
and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be
avoided.
Phase:
Phase 4
Details
Lead Sponsor:
Royal Brompton & Harefield NHS Foundation Trust
Collaborators:
Chelsea and Westminster NHS Foundation Trust Imperial College Healthcare NHS Trust